Canagliflozin for weight loss in non-diabetic individuals
DOI:
https://doi.org/10.18203/2320-6012.ijrms20232459Keywords:
Canagliflozin, Weight loss, Non-diabetics, Obesity, Sodium-glucose co-transporter 2 inhibitors, Anti-diabetic medicationAbstract
Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is primarily used as an anti-diabetic medication, but recent evidence suggests its potential role in promoting weight loss in individuals without diabetes. A comprehensive literature review was conducted, analysing relevant studies published between 2013-2021, focusing on the efficacy and safety of canagliflozin for weight loss in non-diabetic populations. Four relevant studies were identified, which consistently demonstrated that canagliflozin treatment in non-diabetic individuals resulted in significant weight loss compared to placebo or other comparators. The weight loss effect of canagliflozin appears to be mediated by increased urinary glucose excretion, caloric loss, and reduction in body fat mass. Canagliflozin also showed improvements in cardiometabolic risk factors, such as blood pressure and lipid profiles. This review, therefore, provides substantial evidence supporting the potential use of canagliflozin as an effective treatment for weight loss in non-diabetic individuals, suggesting it could be a valuable therapeutic option for addressing the rising prevalence of obesity and associated comorbidities. However, further well-designed clinical trials are needed to elucidate the optimal dosing, long-term safety, and potential side effects of canagliflozin in this specific population.
Metrics
References
Kaushal S, Singh H, Thangaraju P, Singh J. Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus. N Am J Med Sci. 2014;6(3):107-13.
Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128(4):371-80.
Ji W, Zhao M, Wang M, Yan W, Liu Y, Ren S, et al. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS One. 2017;12(6):e0179960.
Roy S. Administration of Once-daily Canagliflozin to a Non-diabetic Patient in Addition to Standard Aerobic Exercise: A Case Report. Cureus. 2019;11(4):e4352.
Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014;22(4):1042-9.
Zheng H, Liu M, Li S, Shi Q, Zhang S, Zhou Y, et al. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:706914.
Napolitano A, Miller S, Murgatroyd PR, Hussey E, Dobbins RL, Bullmore ET, et al. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J Clin Transl Endocrinol. 2013;1(1):3-8.
Bray GA, Ryan DH. Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes. Diabetes Obes Metab. 2021;23(1):50-62.
Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-23.
Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128(4):371-80.
Nisly SA, Kolanczyk DM, Walton AM. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. Am J Health Syst Pharm. 2013;70(4):311-9.
Bray GA, Ryan DH. Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes. Diabetes Obes Metab. 2021;23(1):50-62.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-306.
Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57.
Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019;12:209-15.
Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, et al. CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. Diabetes Obes Metab. 2019;21(3):691-9.
Kruger D, Valentine V. Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review. Diabetes Ther. 2020;11(6):1237-50.
Downloads
Published
How to Cite
Issue
Section
